Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Douglas Goodin, MD

    TitleProfessor in Residence
    SchoolUCSF School of Medicine
    DepartmentNeurology
    Address675 Nelson Rising Lane
    San Francisco CA 94158
    Phone415-514-2464
    Emaildouglas.goodin@ucsf.edu

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Goodin DS. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin Neurol. 2013 Feb; 33(1):13-25.
        View in: PubMed
      2. Goodin DS. The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. PLoS One. 2012; 7(12):e47875.
        View in: PubMed
      3. Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNß-1b study. BMJ Open. 2012; 2(6).
        View in: PubMed
      4. Goodin DS, Reder AT. Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2.
        View in: PubMed
      5. Goodin DS, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
        View in: PubMed
      6. Goodin DS, Reder AT. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
        View in: PubMed
      7. Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies. J Neuroinflammation. 2012; 9:129.
        View in: PubMed
      8. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012; 7(5):e36847.
        View in: PubMed
      9. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
        View in: PubMed
      10. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology. 2012 Feb 21; 78(8):585-9.
        View in: PubMed
      11. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*. J Clin Neurophysiol. 2012 Feb; 29(1):101-8.
        View in: PubMed
      12. Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol. 2012 Jan; 69(1):129-32.
        View in: PubMed
      13. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
        View in: PubMed
      14. Patsopoulos NA. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
        View in: PubMed
      15. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
        View in: PubMed
      16. Goodin DS. Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road. Mult Scler. 2011 Nov; 17(11):1274-5.
        View in: PubMed
      17. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
        View in: PubMed
      18. Goodin D. Multiple Sclerosis: The Big Questions- The MS Forum Workshop. Int MS J. 2011 Sep; 17(3):100-7.
        View in: PubMed
      19. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 5; 76(14):1222-8.
        View in: PubMed
      20. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664.
        View in: PubMed
      21. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92.
        View in: PubMed
      22. Goodin DS. The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurol. 2010; 10:101.
        View in: PubMed
      23. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50.
        View in: PubMed
      24. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
        View in: PubMed
      25. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 8; 74(23):1877-85.
        View in: PubMed
      26. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009 Oct; 15(10):1175-82.
        View in: PubMed
      27. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
        View in: PubMed
      28. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
        View in: PubMed
      29. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5.
        View in: PubMed
      30. Tien I, Glaser SD, Bajcsy R, Goodin DS, Aminoff MJ. Results of using a wireless inertial measuring system to quantify gait motions in control subjects. IEEE Trans Inf Technol Biomed. 2010 Jul; 14(4):904-15.
        View in: PubMed
      31. Goodin D. The 2nd world congress on controversies in neurology. Int MS J. 2009 Apr; 16(1):33-4.
        View in: PubMed
      32. Arnold DL, Goodin DS. Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses. Ann Neurol. 2009 Mar; 65(3):237-8.
        View in: PubMed
      33. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One. 2009; 4(2):e4565.
        View in: PubMed
      34. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009 Mar 3; 72(9):800-5.
        View in: PubMed
      35. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008 Dec 9; 71(24 Suppl 3):S8-13.
        View in: PubMed
      36. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9.
        View in: PubMed
      37. Ralph JW, Goodin DS, Long JM, Aminoff MJ. Electrical brain events associated with awareness of errors. Brain Res. 2009 Jan 28; 1251:213-22.
        View in: PubMed
      38. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78.
        View in: PubMed
      39. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 Sep 2; 71(10):766-73.
        View in: PubMed
      40. Goodin DS. The impact of war-stress on MS exacerbations. Ann Neurol. 2008 Aug; 64(2):114-5.
        View in: PubMed
      41. Goodin D. Comparative studies of glatiramer acetate and interferon beta. Int MS J. 2008 Jun; 15(2):39-41.
        View in: PubMed
      42. Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
        View in: PubMed
      43. Aminoff MJ, Goodin DS. Electrophysiological evaluation of dementia. Handb Clin Neurol. 2008; 89:63-74.
        View in: PubMed
      44. Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007 Nov; 23(11):2823-32.
        View in: PubMed
      45. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
        View in: PubMed
      46. Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res. 2007 Mar-Apr; 35(2):173-87.
        View in: PubMed
      47. Goodin D. Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain. 2006 Dec; 129(Pt 12):e56; author reply e57.
        View in: PubMed
      48. Goodin DS. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006 Oct 10; 67(7):1313-4.
        View in: PubMed
      49. Goodin D. The use of MRI in the diagnosis of multiple sclerosis. Lancet Neurol. 2006 Oct; 5(10):808-9.
        View in: PubMed
      50. Goodin DS. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 Sep 26; 67(6):1104; author reply 1104-5.
        View in: PubMed
      51. Goodin DS. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol. 2006 Jul; 253(7):947-8; author reply 949.
        View in: PubMed
      52. Goodin D. The return of natalizumab: weighing benefit against risk. Lancet Neurol. 2006 May; 5(5):375-7.
        View in: PubMed
      53. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol. 2006 Apr; 59(4):597-605.
        View in: PubMed
      54. Goodin DS, Frohman EM. Overdiagnosis of multiple sclerosis by magnetic resonance imaging. Ann Neurol. 2006 Mar; 59(3):575-6; author reply 576.
        View in: PubMed
      55. Goodin DS. Treatment of multiple sclerosis with human beta interferon. Int MS J. 2005 Nov; 12(3):96-108.
        View in: PubMed
      56. Goodin DS. Evidence-based medicine. Int MS J. 2005 Nov; 12(3):94-5.
        View in: PubMed
      57. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005 Nov; 62(11):1681-3.
        View in: PubMed
      58. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005 Dec 15; 239(1):67-74.
        View in: PubMed
      59. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005 May; 62(5):785-92.
        View in: PubMed
      60. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004 Dec 14; 63(11):2039-45.
        View in: PubMed
      61. Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol. 2004 Sep; 251 Suppl 5:v3-v11.
        View in: PubMed
      62. Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response. J Neurol. 2004 Sep; 251 Suppl 5:v50-v56.
        View in: PubMed
      63. Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, Wechsler LR, Newell DW, Gomez CR, Babikian VL, Lefkowitz D, Goldman RS, Armon C, Hsu CY, Goodin DS. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2004 May 11; 62(9):1468-81.
        View in: PubMed
      64. Goodin DS. Relationship between multiple sclerosis exacerbations and stress. Psychosom Med. 2004 Mar-Apr; 66(2):287-9; author reply 287-9.
        View in: PubMed
      65. Goodin D. Marijuana and multiple sclerosis. Lancet Neurol. 2004 Feb; 3(2):79-80.
        View in: PubMed
      66. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004 Jan; 74(1):160-7.
        View in: PubMed
      67. Leppert D, Goodin DS, Aminoff MJ. Stimulus recognition and its relationship to the cerebral event-related potential. Neurology. 2003 Dec 9; 61(11):1533-7.
        View in: PubMed
      68. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Nov 25; 61(10):1332-8.
        View in: PubMed
      69. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 9; 61(5):602-11.
        View in: PubMed
      70. Goodin DS. Interferons in relapsing remitting multiple sclerosis. Lancet. 2003 May 24; 361(9371):1821; author reply 1823-4.
        View in: PubMed
      71. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003 Mar; 72(3):710-6.
        View in: PubMed
      72. Corboy JR, Goodin DS, Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2003 Jan; 5(1):35-54.
        View in: PubMed
      73. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002 Nov 26; 59(10):1496-506.
        View in: PubMed
      74. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol. 2002 Jun; 22(2):105-22.
        View in: PubMed
      75. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 Jan 22; 58(2):169-78.
        View in: PubMed
      76. Aminoff JC, Goodin DS. Long-latency cerebral event-related potentials in multiple sclerosis. J Clin Neurophysiol. 2001 Jul; 18(4):372-7.
        View in: PubMed
      77. Goodin DS. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response. Drugs. 2001; 61(12):1693-703.
        View in: PubMed
      78. Evans RW, Armon C, Frohman EM, Goodin DS. Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2000 Oct 10; 55(7):909-14.
        View in: PubMed
      79. Pullman SL, Goodin DS, Marquinez AI, Tabbal S, Rubin M. Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2000 Jul 25; 55(2):171-7.
        View in: PubMed
      80. Goodin DS. Therapeutic developments in multiple sclerosis. Expert Opin Investig Drugs. 2000 Apr; 9(4):655-70.
        View in: PubMed
      81. Aminoff MJ, Goodin DS. Studies of the human stretch reflex. Muscle Nerve Suppl. 2000; 9:S3-6.
        View in: PubMed
      82. Goodin DS. The cladribine trial in secondary progressive MS: response. Neuroepidemiology. 2000 Jan-Feb; 19(1):53-4.
        View in: PubMed
      83. Siedenberg R, Goodin DS, Aminoff MJ. Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease. Muscle Nerve. 1999 Nov; 22(11):1557-63.
        View in: PubMed
      84. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1999 Jun 10; 52(9):1737-45.
        View in: PubMed
      85. Goodin DS, Aminoff MJ, Kutukcu Y, Marks WJ. Order effects in response times of parkinsonian patients and normal controls. Muscle Nerve. 1999 May; 22(5):567-72.
        View in: PubMed
      86. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler. 1999 Apr; 5(2):78-88.
        View in: PubMed
      87. Goodin DS. Interferon beta treatment for multiple sclerosis. Lancet. 1999 Feb 6; 353(9151):495-6; author reply 497-8.
        View in: PubMed
      88. Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ. Simple and choice reaction time in Parkinson's disease. Brain Res. 1999 Jan 9; 815(2):367-72.
        View in: PubMed
      89. Heinze HJ, Münte TF, Kutas M, Butler SR, Näätänen R, Nuwer MR, Goodin DS. Cognitive event-related potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52:91-5.
        View in: PubMed
      90. Mauguière F, Allison T, Babiloni C, Buchner H, Eisen AA, Goodin DS, Jones SJ, Kakigi R, Matsuoka S, Nuwer M, Rossini PM, Shibasaki H. Somatosensory evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52:79-90.
        View in: PubMed
      91. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999; 18(2):53-63.
        View in: PubMed
      92. Goodin DS. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler. 1998 Oct; 4(5):444-51.
        View in: PubMed
      93. Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ. Cerebral accompaniments to simple and choice reaction tasks in Parkinson's disease. Brain Res. 1998 Jul 13; 799(1):1-5.
        View in: PubMed
      94. Goodin DS, Aminoff MJ. Event-related potentials in the study of sensory discrimination and motor response in simple and choice reaction tasks. J Clin Neurophysiol. 1998 Jan; 15(1):34-43.
        View in: PubMed
      95. Goodin DS. Cognitive event-related potentials. J Clin Neurophysiol. 1998 Jan; 15(1):2.
        View in: PubMed
      96. Aminoff MJ, Goodin DS. The decision to make a movement: neurophysiological insights. Can J Neurol Sci. 1997 Aug; 24(3):181-90.
        View in: PubMed
      97. Aminoff MJ, Siedenberg R, Goodin DS. Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch during isometric contractions in patients with Parkinson's disease. Brain Res. 1997 May 23; 757(2):254-9.
        View in: PubMed
      98. Goodin DS, Aminoff MJ, Chequer RS, Ortiz TA. Response compatibility and the relationship between event-related potentials and the timing of a motor response. J Neurophysiol. 1996 Dec; 76(6):3705-13.
        View in: PubMed
      99. Goodin DS, Aminoff MJ. Nonrandom behavior in a reaction-time time series. Muscle Nerve. 1996 Sep; 19(9):1183-5.
        View in: PubMed
      100. Siedenberg R, Goodin DS, Aminoff MJ, Rowley HA, Roberts TP. Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields. Electroencephalogr Clin Neurophysiol. 1996 Aug; 99(2):191-7.
        View in: PubMed
      101. Goodin DS, Aminoff MJ, Ortiz TA, Chequer RS. Response times and handedness in simple reaction-time tasks. Exp Brain Res. 1996 Apr; 109(1):117-26.
        View in: PubMed
      102. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996 Feb; 46(2):552-4.
        View in: PubMed
      103. Garcia PA, Aminoff MJ, Goodin DS. The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's disease. Neurology. 1995 May; 45(5):989-92.
        View in: PubMed
      104. Aminoff MJ, Goodin DS. Visual evoked potentials. J Clin Neurophysiol. 1994 Sep; 11(5):493-9.
        View in: PubMed
      105. Husted CA, Matson GB, Adams DA, Goodin DS, Weiner MW. In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging. Ann Neurol. 1994 Aug; 36(2):239-41.
        View in: PubMed
      106. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994 Aug; 36(2):157-65.
        View in: PubMed
      107. Goodin D, Desmedt J, Maurer K, Nuwer MR. IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):18-20.
        View in: PubMed
      108. Nuwer MR, Aminoff M, Desmedt J, Eisen AA, Goodin D, Matsuoka S, Mauguière F, Shibasaki H, Sutherling W, Vibert JF. IFCN recommended standards for short latency somatosensory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):6-11.
        View in: PubMed
      109. Nuwer MR, Aminoff M, Goodin D, Matsuoka S, Mauguière F, Starr A, Vibert JF. IFCN recommended standards for brain-stem auditory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):12-7.
        View in: PubMed
      110. Chequer RS, Goodin DS, Aminoff MJ, Maeztu C. Late electromyographic activity following stretch in human forearm muscles: physiological role. Brain Res. 1994 Apr 4; 641(2):273-8.
        View in: PubMed
      111. Goodin DS. Treatment of optic neuritis. Neurology. 1993 Dec; 43(12):2731-2.
        View in: PubMed
      112. Goodin DS, Aminoff MJ, Ortiz TA. Expectancy and response strategy to sensory stimuli. Neurology. 1993 Oct; 43(10):2139-42.
        View in: PubMed
      113. Ortiz TA, Goodin DS, Aminoff MJ. Neural processing in a three-choice reaction-time task: a study using cerebral evoked-potentials and single-trial analysis in normal humans. J Neurophysiol. 1993 May; 69(5):1499-512.
        View in: PubMed
      114. Goodin DS. Corticosteroids and optic neuritis. Neurology. 1993 Mar; 43(3 Pt 1):632-3; author reply 633-4.
        View in: PubMed
      115. Goodin DS, Aminoff MJ. Evaluation of dementia by event-related potentials. J Clin Neurophysiol. 1992 Oct; 9(4):521-5.
        View in: PubMed
      116. Goodin DS, Aminoff MJ. The basis and functional role of the late EMG activity in human forearm muscles following wrist displacement. Brain Res. 1992 Aug 28; 589(1):39-47.
        View in: PubMed
      117. Goodin DS, Aminoff MJ, Chequer RS. Effect of different high-pass filters on the long-latency event-related auditory evoked potentials in normal human subjects and individuals infected with the human immunodeficiency virus. J Clin Neurophysiol. 1992 Jan; 9(1):97-104.
        View in: PubMed
      118. Chequer RS, Goodin DS, Aminoff MJ. The nature of suprasegmental influences on the late reflex activity in human forearm muscles. Brain Res. 1991 Dec 6; 566(1-2):284-9.
        View in: PubMed
      119. Goodin DS. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology. 1991 Jul; 41(7):980-5.
        View in: PubMed
      120. Olney RK, So YT, Goodin DS, Aminoff MJ. A comparison of magnetic and electrical stimulation of peripheral nerves. Muscle Nerve. 1990 Oct; 13(10):957-63.
        View in: PubMed
      121. Goodin DS, Aminoff MJ, Shefrin SL. Organization of sensory discrimination and response selection in choice and nonchoice conditions: a study using cerebral evoked potentials in normal humans. J Neurophysiol. 1990 Oct; 64(4):1270-81.
        View in: PubMed
      122. Goodin DS, Aminoff MJ, Shih PY. Evidence that the long-latency stretch responses of the human wrist extensor muscle involve a transcerebral pathway. Brain. 1990 Aug; 113 ( Pt 4):1075-91.
        View in: PubMed
      123. Goodin DS. Clinical utility of long latency 'cognitive' event-related potentials (P3): the pros. Electroencephalogr Clin Neurophysiol. 1990 Jul; 76(1):2-5; discussion 1.
        View in: PubMed
      124. Goodin DS, Aminoff MJ, Chernoff DN, Hollander H. Long latency event-related potentials in patients infected with human immunodeficiency virus. Ann Neurol. 1990 Apr; 27(4):414-9.
        View in: PubMed
      125. Goodin DS, Aminoff MJ, Laxer KD. Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy. Ann Neurol. 1990 Mar; 27(3):330-4.
        View in: PubMed
      126. Aminoff MJ, Goodin A, Goodin DS. Electrophysiological features of the dementia of Parkinson's disease. Adv Neurol. 1990; 53:361-3.
        View in: PubMed
      127. Reisin RC, Goodin DS, Aminoff MJ, Mantle MM. Effects of different sensory inputs on the median-derived somatosensory evoked potential. Muscle Nerve. 1989 Jul; 12(7):598-603.
        View in: PubMed
      128. Shih PY, Aminoff MJ, Goodin DS, Mantle MM. Effect of reference point on visual evoked potentials: clinical relevance. Electroencephalogr Clin Neurophysiol. 1988 Jul-Aug; 71(4):319-22.
        View in: PubMed
      129. Reisin RC, Goodin DS, Aminoff MJ, Mantle MM. Recovery of peripheral and central responses to median nerve stimulation. Electroencephalogr Clin Neurophysiol. 1988 Jun; 69(6):585-8.
        View in: PubMed
      130. Aminoff MJ, Goodin DS. Dermatomal somatosensory evoked potentials in lumbosacral root compression. J Neurol Neurosurg Psychiatry. 1988 May; 51(5):740-2.
        View in: PubMed
      131. Goodin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol. 1988 Apr; 23(4):418-20.
        View in: PubMed
      132. Aminoff MJ, Goodin DS, Berg BO, Compton MN. Ambulatory EEG recordings in epileptic and nonepileptic children. Neurology. 1988 Apr; 38(4):558-62.
        View in: PubMed
      133. Shefrin SL, Goodin DS, Aminoff MJ. Visual evoked potentials in the investigation of "blindsight". Neurology. 1988 Jan; 38(1):104-9.
        View in: PubMed
      134. Goodin DS, Aminoff MJ. PD and ciladopa. Neurology. 1988 Jan; 38(1):167.
        View in: PubMed
      135. Goodin DS, Aminoff MJ, Mantle MM. Sensory discrimination and its relationship to the cerebral processing of infrequent stimuli. Can J Neurol Sci. 1987 Nov; 14(4):642-8.
        View in: PubMed
      136. Aminoff MJ, Goodin DS, Habermann-Little B, Cutler JR. Treatment of Parkinson's disease with ciladopa. Ann Neurol. 1987 Mar; 21(3):311.
        View in: PubMed
      137. Shefrin SL, Goodin DS, Aminoff MJ. Electrophysiological evidence of visual processing in a blind field. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40:752-5.
        View in: PubMed
      138. Goodin DS, Aminoff MJ. The distinction between different types of dementia using evoked potentials. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40:695-8.
        View in: PubMed
      139. Goodin DS, Aminoff MJ. Electrophysiological differences between demented and nondemented patients with Parkinson's disease. Ann Neurol. 1987 Jan; 21(1):90-4.
        View in: PubMed
      140. Goodin DS, Aminoff MJ. Electrophysiological differences between subtypes of dementia. Brain. 1986 Dec; 109 ( Pt 6):1103-13.
        View in: PubMed
      141. Goodin DS, Aminoff MJ, Mantle MM. Subclasses of event-related potentials: response-locked and stimulus-locked components. Ann Neurol. 1986 Nov; 20(5):603-9.
        View in: PubMed
      142. Goodin DS. P300 latency as a biologic marker of dementia. Biol Psychiatry. 1986 Oct; 21(12):1111-3.
        View in: PubMed
      143. Bayne LL, Schmidley JW, Goodin DS. Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G. Arch Neurol. 1986 Feb; 43(2):137-8.
        View in: PubMed
      144. Aminoff MJ, Goodin DS, Parry GJ, Barbaro NM, Weinstein PR, Rosenblum ML. Electrophysiologic evaluation of lumbosacral radiculopathies: electromyography, late responses, and somatosensory evoked potentials. Neurology. 1985 Oct; 35(10):1514-8.
        View in: PubMed
      145. Goodin DS. Electrophysiologic evaluation of dementia. Neurol Clin. 1985 Aug; 3(3):633-47.
        View in: PubMed
      146. Goodin DS, Waltz DA, Aminoff MJ. Task-dependent hemisphere asymmetries of the visual evoked potential. Neurology. 1985 Mar; 35(3):378-84.
        View in: PubMed
      147. Aminoff MJ, Goodin DS, Barbaro NM, Weinstein PR, Rosenblum ML. Dermatomal somatosensory evoked potentials in unilateral lumbosacral radiculopathy. Ann Neurol. 1985 Feb; 17(2):171-6.
        View in: PubMed
      148. Goodin DS, Aminoff MJ. Does the interictal EEG have a role in the diagnosis of epilepsy? Lancet. 1984 Apr 14; 1(8381):837-9.
        View in: PubMed
      149. Goodin DS, Aminoff MJ. The relationship between the evoked potential and brain events in sensory discrimination and motor response. Brain. 1984 Mar; 107 ( Pt 1):241-51.
        View in: PubMed
      150. Goodin DS, Starr A, Chippendale T, Squires KC. Sequential changes in the P3 component of the auditory evoked potential in confusional states and dementing illnesses. Neurology. 1983 Sep; 33(9):1215-8.
        View in: PubMed
      151. Goodin DS, Squires KC, Starr A. Variations in early and late event-related components of the auditory evoked potential with task difficulty. Electroencephalogr Clin Neurophysiol. 1983 Jun; 55(6):680-6.
        View in: PubMed
      152. Goodin DS, Squires KC, Starr A. Long latency event-related components of the auditory evoked potential in dementia. Brain. 1978 Dec; 101(4):635-48.
        View in: PubMed
      153. Goodin DS, Squires KC, Henderson BH, Starr A. An early event-related cortical potential. Psychophysiology. 1978 Jul; 15(4):360-5.
        View in: PubMed
      154. Goodin DS, Squires KC, Henderson BH, Starr A. Age-related variations in evoked potentials to auditory stimuli in normal human subjects. Electroencephalogr Clin Neurophysiol. 1978 Apr; 44(4):447-58.
        View in: PubMed
      155. Mattson T, Richardson J, Goodin D. Mutant of bacteriophage T4D affecting expression of many early genes. Nature. 1974 Jul 5; 250(461):48-50.
        View in: PubMed
      156. Ray WJ, Goodin DS, Ng L. Cobalt (II) and nickel (II) complexes of phosphoglucomutase. Biochemistry. 1972 Jul 18; 11(15):2800-4.
        View in: PubMed
      Douglas's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      See all (381) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (21) people
      _
      Related Authors
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Back to TOP